In clinical trials
Digestive & weight
Brilacidin
Evidence
Clinical trials
Class
Host-defense peptide mimetic
KEY TAKEAWAY
Brilacidin is a synthetic molecule designed to imitate the shape and action of natural defensin peptides. It is not a true peptide but is often grouped with them. Brilacidin is not FDA-approved and has been tested in clinical trials.
Written by the Veylo editorial team · Updated
November 2026
What it is
Host-defense peptide mimetic
Being studied for
Studied for skin infections, oral mucositis and ulcerative proctitis
Key fact
Brilacidin is not FDA-approved and has been tested in clinical trials.
Route
Intravenous, oral rinse and enema forms in trials
Evidence strength
Clinical trials
Brilacidin is a synthetic molecule designed to imitate the shape and action of natural defensin peptides. It is not a true peptide but is often grouped with them.
It disrupts bacterial membranes and also calms inflammation, so it has been tested for infections and for inflammatory conditions of the bowel and mouth.
Brilacidin is not FDA-approved and has been tested in clinical trials.
Studied for skin infections, oral mucositis and ulcerative proctitis.
Trials reported mostly mild effects, and safety data remain limited.
Brilacidin: see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.